Biotech Stocks to Watch AbbVie and MannKind

Off late, Biotech stocks have seen some volatility. Here we look at two promising stocks: Abbvie (NYSE ABBV) and MannKind (NASDAQ MNKD). The two stocks have their fortunes at the opposite end of the spectrum. We take a look at what the future holds for the two stocks. Despite three rejections so far, AbbVie is reportedly still attempting to convince Shire and its major shareholders … Continue reading Biotech Stocks to Watch AbbVie and MannKind

PRAN NASDAQ PRAN Prana Biotechnology

Biotech Stocks : Top Stocks Arena Pharmaceuticals (NASDAQ ARNA) & Bristol-Myers Squibb (NYSE BMY)

Here in this article, we take a look at two very promising stock: Arena Pharmaceuticals (NASDAQ ARNA) & Bristol-Myers Squibb (NYSE BMY). Arena Pharmaceuticals stock (NASDAQ ARNA) has been slightly lukewarm as off late. But that may change with a relaunch on the horizon. Bristol-Myers Squibb have a lot of projects on the horizon which should see the stock flourish in the coming future. Shares … Continue reading Biotech Stocks : Top Stocks Arena Pharmaceuticals (NASDAQ ARNA) & Bristol-Myers Squibb (NYSE BMY)

Biotech stock market news

Biotech Stocks : Review of Johnson & Johnson and Sarepta Therapeutics

In this article, we take a look at two very up and coming stocks in Johnson & Johnson and Sarepta Therapeutics. Keep an eye out for Johnson & Johnson (NYSE JNJ) and Sarepta Therapeutics (NASDAQ SRPT). While at one hand, analysts are optimistic about Johnson & Johnson’s second quarter earnings, Sarepta Therapeutics would be looking to bounce back after some dismal showing recently. With J&J … Continue reading Biotech Stocks : Review of Johnson & Johnson and Sarepta Therapeutics

Biotech Stock Finance Bio Tech

Biotech Stock in News: The Medicines Co.’s Angiomax Gets Favorable Court Ruling

The Medicines Co (MDCO) announced that the U.S. District Court for the Northern District of Illinois has ruled in its favor in a patent infringement lawsuit against Mylan, Inc (MYL). Mylan was looking to get its generic version of The Medicines Co.’s Angiomax (European trade name: Angiox) approved in the U.S. The Medicines Co. stated that the Court declared its patent claims 1-3, 7-10 and … Continue reading Biotech Stock in News: The Medicines Co.’s Angiomax Gets Favorable Court Ruling

PRAN NASDAQ PRAN Prana Biotechnology

Biotech Stock News: Biogen Falls on Concerns Regarding Tecfidera Sales

Despite posting better-than-expected earnings, Biogen Idec’s (BIIB) shares fell 5.4% immediately after the release of third quarter results. Although shares recovered slightly in the subsequent trading session, the overall decline is approximately 3.3% since the announcement of third quarter results. The decline in share price reflects concerns regarding the growth prospects of Biogen’s oral multiple sclerosis (MS) treatment, Tecfidera. Tecfidera, approved in the U.S. in … Continue reading Biotech Stock News: Biogen Falls on Concerns Regarding Tecfidera Sales

Top Biotech Stock News: Biogen’s Q3 Earnings Top Estimates

Biogen Idec (BIIB) reported third quarter 2014 earnings per share of $3.79 (including the impact of stock-based compensation expense), way above the Consensus Estimate of $3.22 and the year-ago earnings of $2.34 per share. Third quarter 2014 revenues increased 37% to $2.5 billion, topping the Consensus Estimate of $2.4 billion. Including one-time items, third quarter 2014 earnings increased 77% to $3.62 per share. Third quarter … Continue reading Top Biotech Stock News: Biogen’s Q3 Earnings Top Estimates